Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

1. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. (PubMed)

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. Importance: Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. It is unknown whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels. Objective: To compare the association of triglyceride-lowering (...) variants in the lipoprotein lipase (LPL) gene and LDL-C-lowering variants in the LDL receptor gene (LDLR) with the risk of cardiovascular disease per unit change in ApoB. Design, Setting, and Participants: Mendelian randomization analyses evaluating the associations of genetic scores composed of triglyceride-lowering variants in the LPL gene and LDL-C-lowering variants in the LDLR gene, respectively, with the risk of cardiovascular events among participants enrolled in 63 cohort or case-control studies

2019 JAMA

2. Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Signal - Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Dissemination Centre Discover Portal NIHR DC Discover Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Published on 5 December 2017 A combination of providing clean needles and syringes and offering safer oral (...) therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection. Current services are estimated to save up to £54 million in costs of treating hepatitis C infection. This is in addition to the savings made

2019 NIHR Dissemination Centre

3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. (PubMed)

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. BACKGROUND: The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated

Full Text available with Trip Pro

2019 Lancet

4. C-reactive protein for diagnosing late-onset infection in newborn infants. (PubMed)

C-reactive protein for diagnosing late-onset infection in newborn infants. BACKGROUND: Late-onset infection is the most common serious complication associated with hospital care for newborn infants. Because confirming the diagnosis by microbiological culture typically takes 24 to 48 hours, the serum level of the inflammatory marker C-reactive protein (CRP) measured as part of the initial investigation is used as an adjunctive rapid test to guide management in infants with suspected late-onset (...) infection. OBJECTIVES: To determine the diagnostic accuracy of serum CRP measurement in detecting late-onset infection in newborn infants. SEARCH METHODS: We searched electronic databases (MEDLINE, Embase, and Science Citation Index to September 2017), conference proceedings, previous reviews, and the reference lists of retrieved articles. SELECTION CRITERIA: We included cohort and cross-sectional studies evaluating the diagnostic accuracy of serum CRP levels for the detection of late-onset infection

2019 Cochrane

5. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. (PubMed)

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. OBJECTIVES: To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. DESIGN: Nested case-control study. SETTING: 20 population based cohort studies in Asia

2019 BMJ

6. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes - GOV.UK GOV.UK uses cookies to make the site simpler. Search Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first (...) 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic treatment is continued at the same dose due to potential for an enhanced hypoglycaemic effect. Published 18 December 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: rapid reduction in hepatitis C viral load during direct-acting antiviral therapy for hepatitis C may lead to improvements in glucose metabolism

2019 MHRA Drug Safety Update

7. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, November 2018 PDF Print ISBN 978-92-9498-286-5 ISBN 978-92-9498-294-0 DOI 10.2900/79127 DOI 10.2900/489464 Catalogue number TQ-06-18-328-EN-N Catalogue number TQ-06-18-328-EN-C © European Centre for Disease Prevention and Control, 2018 Cover picture: © iStock Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material

2019 European Centre for Disease Prevention and Control - Public Health Guidance

8. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

9. Pharmacological interventions for acute hepatitis C infection. (PubMed)

Pharmacological interventions for acute hepatitis C infection. BACKGROUND: Hepatitis C virus (HCV) is a single-stranded RNA (ribonucleic acid) virus that has the potential to cause inflammation of the liver. The traditional definition of acute HCV infection is the first six months following infection with the virus. Another commonly used definition of acute HCV infection is the absence of HCV antibody and subsequent seroconversion (presence of HCV antibody in a person who was previously

2018 Cochrane

10. Drugs for hepatitis C: it's time to slash prices!

Drugs for hepatitis C: it's time to slash prices! Prescrire IN ENGLISH - Spotlight ''Drugs for hepatitis C: it's time to slash prices!'', 1 December 2018 {1} {1} {1} | | > > > Drugs for hepatitis C: it's time to slash prices! Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drugs for hepatitis C: it's time to slash prices! The high prices (...) of hepatitis C drugs are an obstacle to treatment for most of the people around the world who are infected by the virus. When so-called direct-acting antiviral drugs against hepatitis C came onto the market around 2015, some stakeholders hailed them as a means of eradicating this disease. Sofosbuvir (Sovaldi°) was marketed in the United States at the exorbitant price of 1000 dollars per day, reflecting the company's strategy of seeking maximum profits in the richest countries and not eradication

2018 Prescrire

11. Vitamin C blood level testing

Vitamin C blood level testing Haute Autorité de Santé - Dosage de la vitamine C dans le sang Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Outils, Guides & Méthodes Évaluation des technologies de santé Dosage de la vitamine C dans le sang Date de validation mai 2018 Contexte - Objectif Le dosage de la vitamine C dans le sang se situe parmi les 60 examens de la liste complémentaire du Référentiel des actes innovants hors (...) nomenclature (RIHN) les plus réalisés en 2016, avec plus de 40 000 dosages déclarés à la DGOS par les établissements de santé français, soit un coût de plus d’un million d’euros (dosage référencé sous les codes K092, K093 et K174). S’il est reconnu qu’une carence profonde et prolongée en vitamine C peut entraîner la survenue de manifestations cliniques caractéristiques du scorbut, cette affection est de nos jours très rare et son diagnostic ne peut a priori pas expliquer ce nombre de dosages. Or, en marge

2018 Haute Autorite de sante

12. Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate (PubMed)

Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate 30396911 2018 12 07 2473-9537 2 21 2018 Nov 13 Blood advances Blood Adv Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. 2917-2921 10.1182/bloodadvances.2018024430 Bendapudi Pavan K PK Division of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA. Division

Full Text available with Trip Pro

2018 Blood advances

13. Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block (PubMed)

Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block 30411074 2018 11 14 2471-254X 2 11 2018 Nov Hepatology communications Hepatol Commun Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block. 1289-1292 10.1002/hep4.1261 Editorial to Leung et al. "Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4". Indolfi Giuseppe G Pediatric and Liver

Full Text available with Trip Pro

2018 Hepatology communications

14. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-55 Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35 1 Translation of addendum A18-05 Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) – Addendum zum Auftrag A17-35 (Version 1.0; Status: 25 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 January 2018 1.0 Commission: A18-05 Version (...) : Status: IQWiG Reports – Commission No. A18-05 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35 1 Addendum A18-05 Version 1.0 Sofosbuvir/velpatasvir/voxilaprevir – Addendum to Commission A17-35 25 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER

Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER 30270178 2018 11 16 1879-1913 122 11 2018 Dec 01 The American journal of cardiology Am. J. Cardiol. Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis (...) of HIJ-PROPER. 1817-1823 S0002-9149(18)31727-2 10.1016/j.amjcard.2018.08.028 The systematic inflammatory response might confound renal impairment, and both have been reported to affect clinical outcomes after acute coronary syndrome. We examined the impacts of the high-sensitivity C-reactive protein (hsCRP) level and estimated glomerular filtration rate level on the prognosis for acute coronary syndrome patients who underwent aggressive lipid-lowering therapy in contemporary practice

2018 EvidenceUpdates

17. Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract (PubMed)

Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract 30417049 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract. 389-394 10.3233/BLC-180174 Results of randomized trials support a single dose of intravesical (...) chemotherapy following radical nephroureterectomy (RNU) for urothelial carcinoma. To evaluate the impact of the timing of intravesical mitomycin C (MMC) administration on the rate of bladder tumor recurrence (BTR) following RNU. We performed a retrospective review of patients who underwent RNU for upper tract urothelial carcinoma (UTUC) and received intravesical MMC between 2008 and 2016. Patients were categorized into two separate groups based on the timing of MMC administration: patients who received MMC

Full Text available with Trip Pro

2018 Bladder cancer (Amsterdam, Netherlands)

18. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C (...) -CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update Sheldon W. Tobe , James A. Stone , Todd Anderson , Simon Bacon , Alice Y.Y. Cheng , Stella S. Daskalopoulou , Justin A. Ezekowitz , Jean C. Gregoire , Gord Gubitz , Rahul Jain , Karim Keshavjee , Patty Lindsay , Mary L’Abbe , David C.W. Lau , Lawrence A. Leiter , Eileen O’Meara , Glen J. Pearson , Doreen M. Rabi , Diana Sherifali , Peter Selby , Jack V. Tu , Sean Wharton , Kimberly M. Walker

2018 CPG Infobase

19. Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy (PubMed)

Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy 30411077 2018 11 14 2471-254X 2 11 2018 Nov Hepatology communications Hepatol Commun Evaluating Women's Preferences for Hepatitis C Treatment During Pregnancy. 1306-1310 10.1002/hep4.1264 There is a rising prevalence of hepatitis C (HCV) among women of child-bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy (...) of Gastroenterology/Hepatology University of California San Francisco San Francisco CA. Division of Liver Diseases Icahn School of Medicine at Mount Sinai New York NY. Cohen Jennifer J Department of Clinical Pharmacy University of California San Francisco CA. Tien Phyllis C PC Division of Gastroenterology/Hepatology University of California San Francisco San Francisco CA. San Francisco Veterans Affairs Medical Center San Francisco CA. Terrault Norah A NA Division of Gastroenterology/Hepatology University

Full Text available with Trip Pro

2018 Hepatology communications

20. Bezlotoxumab (Zinplava) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity

Bezlotoxumab (Zinplava) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity Prescrire IN ENGLISH - Spotlight ''Bezlotoxumab (Zinplava°) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity'', 1 October 2018 {1} {1} {1} | | > > > Bezlotoxumab (Zinplava°) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity Spotlight Every month (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Bezlotoxumab (Zinplava°) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity FEATURED REVIEW Given the serious complications associated with Clostridium difficile infection, treatment that safely reduces the risk of recurrences in high-risk patients would constitute

2018 Prescrire